

IN THE CLAIMS

1.-37. (Cancelled)

38. (Currently Amended) A composition for the inhibition of heparanase glycosidase catalytic activity, consisting essentially of, as a first constituent, a pharmaceutically acceptable material selected from the group consisting of a carrier, a diluent, an excipient and an additive, and, as a second constituent ~~one of eosinophil cell lysate, eosinophil secondary granules basic protein, poly-L-arginine and mixtures thereof, wherein the second constituent is present in a concentration of about from 1 to about 180 µg/ml, wherein the eosinophil secondary granules basic protein is the 117 amino acid residue of MBP (Major Basic Protein).~~

39. (Cancelled)

40. (Cancelled)

41. (Currently Amended) A composition according to claim 39, wherein said eosinophil secondary granules basic protein is provided as one of a purified recombinant protein, a fusion protein, ~~a nucleic acid construct encoding for said protein, a host cell expressing said construct, a cell, a cell line, tissue endogeneously expressing said protein and a lysate thereof.~~

42. (Currently Amended) A method for the inhibition of heparanase glycosidase catalytic activity in a subject in need thereof consisting essentially of the step of administering to the subject ~~one of eosinophil cell lysate, a therapeutically effective amount of an eosinophil secondary granules basic protein and mixtures thereof which is the 117 amino acid residue of MBP (Major Basic Protein)~~ in a concentration of from about 1 to about 180 µg/ml.

43. (Cancelled)

44. (Cancelled).

45. (Currently Amended) The method according to claim 43, wherein the eosinophil secondary granules basic protein is provided as any one of a purified recombinant protein, a fusion protein, ~~a nucleic acid construct encoding for said protein, a host cell expressing said construct,~~ a cell, a cell line and a tissue endogeneously expressing said protein or a lysate thereof.

46. (Currently Amended) Method for preparation of a composition for the inhibition of heparanase glycosidase catalytic activity consisting essentially of the step of formulating a first constituent composed of a pharmaceutically acceptable material selected from the group ~~containing~~ consisting of a carrier, a diluent, an excipient and an additive with a second constituent composed of ~~one of eosinophil cell lysate~~, an eosinophil secondary granules basic protein, ~~and mixtures thereof which is the 117 amino acid residue of MBP (Major Basic Protein)~~ in a concentration of from about 1 to about 180 µg/ml.

47. (Cancelled)

48. (Currently Amended) The method according to claim 46, wherein the eosinophil secondary granules basic protein is one of a purified recombinant protein, a fusion protein, ~~a nucleic acid construct encoding for said protein, a host cell expressing said construct,~~ a cell, a cell line, a tissue endogeneously expressing said protein and a lysate thereof.

49. (Currently Amended) A method for the inhibition of heparanase glycosidase catalytic activity consisting essentially of the step of contacting cells having heparanase glycosidase catalytic activity with ~~one of eosinophil cell lysate~~, an eosinophil secondary granules basic protein ~~and mixtures thereof which is the 117 amino acid residue of MBP (Major Basic Protein)~~ in a concentration of from about 1 to about 180 µg/ml.